Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6311312 | 1.00 | ALDH1A1 (0.55) | ALDH1A1NPC1GLAPOLBLMNA | |
| SCHEMBL5783680 | 0.81 | ALDH1A1 (0.57) | ALDH1A1NPC1POLBLMNAMAPT | |
| SCHEMBL19847946 | 0.80 | ALDH1A1 (0.52) | ALDH1A1NPC1POLBLMNAMAPT | |
| SCHEMBL10529630 | 0.80 | ALDH1A1 (0.57) | ALDH1A1NPC1POLBLMNAMAPT | |
| SCHEMBL6730228 | 0.79 | NPC1 (0.54) | ALDH1A1NPC1POLBLMNAMAPT | |
| SCHEMBL4750821 | 0.78 | ALDH1A1 (0.39) | ALDH1A1NPC1GLAPOLBLMNA | |
| SCHEMBL4753146 | 0.78 | HTR2A (0.47) | ALDH1A1NPC1GLAKMT2ASMN1; SMN2 | |
| SCHEMBL17525886 | 0.78 | NPC1 (0.56) | ALDH1A1NPC1POLBLMNAMAPT | |
| SCHEMBL7819650 | 0.77 | NPC1 (0.55) | ALDH1A1NPC1POLBLMNAMAPT | |
| SCHEMBL7963661 | 0.77 | NPC1 (0.55) | ALDH1A1NPC1POLBLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844344-B2 | Benzofuran derivatives | ELI LILLY AND COMPANY (US) | 2005-01-18 | — | — | US | disclosed |
| US-20040186170-A1 | Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient | EGIS GYOGYSZERGYAR (HU) | 2004-09-23 | — | — | US | disclosed |
| US-20030232833-A1 | Benzofuran derivatives | ELI LILLY AND COMPANY | 2003-12-18 | — | — | US | disclosed |
| EP-1246822-A1 | BENZOFURAN DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001046177-A1 | BENZOFURAN DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-1077973-A2 | BENZOFURAN DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND A PROCESS FOR THE PREPARATION OF THE ACTIVE INGREDIENT | EGIS GYOGYSZERGYAR RT. (HU) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058527-A2 | BENZOFURAN DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND A PROCESS FOR THE PREPARATION OF THE ACTIVE INGREDIENT | EGIS Gyógyszergyár Rt. (HU) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186170-A1 | Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient | CYP2F1, CYP3A4, CYP2S1 | ALDH1A1 81/4885NPC1 2097/4885GLA 2247/4885 |
| US-20030232833-A1 | Benzofuran derivatives | BRD1, BPTF, HTR1F | ALDH1A1 90/4885NPC1 3324/4885GLA 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.